Topline data were announced from a phase 3 trial evaluating secukinumab in patients with polymyalgia rheumatica.

Novartis said that its immunology drug Cosentyx met the primary target and all secondary ones in a late-stage trial for the treatment of patients with inflammatory disease polymyalgia rheumatica.

Actor Rajesh Keshav, who has been undergoing treatment following a heart attack, is showing signs of progress. According to ...

After enduring a heart attack, Malayalam anchor Rajesh Keshav is showing promising signs of recovery. After two months of ...

Late-breaking Phase III data show ianalumab, Novartis’ dual-targeted antibody, reduced disease activity and patient burden in ...

Learn about neck pain causes, evaluation, management, and prevention strategies to maintain a healthy neck in the digital age ...

More than 30% of patients with rheumatic disease, and more than 40% of those with rheumatoid arthritis, experienced flares ...

Fibromyalgia was considered a comorbidity rather than a rheumatic disease, but was present in about 10% of patients. Other ...

Outer Banks Voice Donna Boston, a 63-year-old surfer who learned in her early 50’s, says that for women, participating in the sport can be daunting.

Opioid prescribing appears to be prevalent among older adults with rheumatic diseases, according to results presented at the American College of Rheumatology (ACR) Convergence 2025.

Q3 2025 Earnings Call Transcript October 28, 2025 Novartis AG misses on earnings expectations. Reported EPS is $2.25 EPS, ...